Literature DB >> 21915646

Cerebral venous and sinus thrombosis associated with subcutaneous immunoglobulin injection and oral contraceptive use.

Jiangyong Min1, Archit Bhatt, Rany Aburashed, Stephen Burton.   

Abstract

Although patients of cerebral sinus thrombosis after intravenous immunoglobulin (IVIG) has been previously reported; reports of cerebral venous thrombosis secondary to subcutaneous injection of immunoglobulin (SIG) in conjunction with oral contraceptives are nonexistent in the current literature. We describe here a patient of cerebral venous and sinus thrombosis occurring after the combination of SIG and oral contraceptive use. Furthermore, we shall explore proper clinical precautions for someone who receives IG therapy, especially in conjunction with the use of oral contraceptives.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21915646     DOI: 10.1007/s10072-011-0778-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  10 in total

1.  Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations.

Authors:  A S Wolberg; R H Kon; D M Monroe; M Hoffman
Journal:  Am J Hematol       Date:  2000-09       Impact factor: 10.047

2.  Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders.

Authors:  J A Grillo; K C Gorson; A H Ropper; J Lewis; R Weinstein
Journal:  Neurology       Date:  2001-11-13       Impact factor: 9.910

Review 3.  Oral contraceptives and the risk of venous thrombosis.

Authors:  J P Vandenbroucke; J Rosing; K W Bloemenkamp; S Middeldorp; F M Helmerhorst; B N Bouma; F R Rosendaal
Journal:  N Engl J Med       Date:  2001-05-17       Impact factor: 91.245

4.  Transverse sinus thrombosis and IVIg treatment: a case report and discussion of risk-benefit assessment for immunoglobulin treatment.

Authors:  N Evangelou; T Littlewood; P Anslow; H Chapel
Journal:  J Clin Pathol       Date:  2003-04       Impact factor: 3.411

5.  Increased risk of cerebral venous sinus thrombosis with third-generation oral contraceptives. Cerebral Venous Sinus Thrombosis Study Group.

Authors:  S F de Bruijn; J Stam; J P Vandenbroucke
Journal:  Lancet       Date:  1998-05-09       Impact factor: 79.321

Review 6.  Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.

Authors:  I Marie; G Maurey; F Hervé; M-F Hellot; H Levesque
Journal:  Br J Dermatol       Date:  2006-10       Impact factor: 9.302

Review 7.  Intravenous immunoglobulin-related acute coronary syndrome and coronary angiography in idiopathic thrombocytopenic purpura--a case report and literature review.

Authors:  Eron D Crouch; Linley E Watson
Journal:  Angiology       Date:  2002 Jan-Feb       Impact factor: 3.619

8.  Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases.

Authors:  Y Sherer; Y Levy; P Langevitz; L Rauova; F Fabrizzi; Y Shoenfeld
Journal:  Pharmacology       Date:  2001       Impact factor: 2.547

9.  Cerebral venous thrombosis--a review of 38 cases.

Authors:  M G Bousser; J Chiras; J Bories; P Castaigne
Journal:  Stroke       Date:  1985 Mar-Apr       Impact factor: 7.914

10.  High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives.

Authors:  I Martinelli; E Sacchi; G Landi; E Taioli; F Duca; P M Mannucci
Journal:  N Engl J Med       Date:  1998-06-18       Impact factor: 91.245

  10 in total
  2 in total

Review 1.  The etiologies of new cases of cerebral venous sinus thrombosis reported in the past year.

Authors:  Ran Meng; Xunming Ji; Xiaoying Wang; Yuchuan Ding
Journal:  Intractable Rare Dis Res       Date:  2012-02

Review 2.  On the dark side of therapies with immunoglobulin concentrates: the adverse events.

Authors:  Peter J Späth; Guido Granata; Fabiola La Marra; Taco W Kuijpers; Isabella Quinti
Journal:  Front Immunol       Date:  2015-02-05       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.